These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38634691)

  • 1. Insulin resistance impairs biologic agent response in moderate-to-severe plaque psoriasis: insights from a prospective cohort study in China.
    Huang D; Zhong X; Jiang Y; Kong L; Ma R; Lu J; Li Y; Shi Y
    Br J Dermatol; 2024 Sep; 191(4):616-623. PubMed ID: 38634691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
    Cochrane Database Syst Rev; 2022 May; 5(5):CD011535. PubMed ID: 35603936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR).
    Mahil SK; Wilson N; Dand N; Reynolds NJ; Griffiths CEM; Emsley R; Marsden A; Evans I; Warren RB; Stocken D; Barker JN; Burden AD; Smith CH;
    Br J Dermatol; 2020 May; 182(5):1158-1166. PubMed ID: 31286471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial.
    Al-Mutairi N; Nour T
    Expert Opin Biol Ther; 2014 Jun; 14(6):749-56. PubMed ID: 24661040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis.
    Robinson A; Kardos M; Kimball AB
    J Am Acad Dermatol; 2012 Mar; 66(3):369-75. PubMed ID: 22041254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Comparison of Psoriasis Severity in Pediatric Patients Treated With Methotrexate vs Biologic Agents.
    Bronckers IMGJ; Paller AS; West DP; Lara-Corrales I; Tollefson MM; Tom WL; Hogeling M; Belazarian L; Zachariae C; Mahé E; Siegfried E; Blume-Peytavi U; Szalai Z; Vleugels RA; Holland K; Murphy R; Puig L; Cordoro KM; Lambert J; Alexopoulos A; Mrowietz U; Kievit W; Seyger MMB;
    JAMA Dermatol; 2020 Apr; 156(4):384-392. PubMed ID: 32022846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis.
    Cai L; Jiang C; Zhang G; Fang H; Wang J; Li Y; Xu H; Xiao R; Ding Y; Huang K; Zhang C; Zhang L; Chen B; Duan X; Pan W; Han G; Chen R; Liu L; Zhang S; Tao J; Pang X; Yu J; Wang H; Zhao Y; Li C; Kang X; Qin L; Zhu X; Su J; Li S; Yang C; Feng W; Lei T; Jiang S; Fang R; Lin M; Lu Q; Xu C; Wang W; Zhang J
    Br J Dermatol; 2024 Aug; 191(3):336-343. PubMed ID: 38366639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antistreptococcal interventions for guttate and chronic plaque psoriasis.
    Dupire G; Droitcourt C; Hughes C; Le Cleach L
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD011571. PubMed ID: 30835819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28.
    Papp KA; Reich K; Blauvelt A; Kimball AB; Gooderham M; Tyring SK; Sinclair R; Thaci D; Li Q; Cichanowitz N; Green S; La Rosa C
    J Eur Acad Dermatol Venereol; 2019 Jun; 33(6):1098-1106. PubMed ID: 30838709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter, prospective, observational study examining the impact of risk factors, such as BMI and waist circumference, on quality of life improvement and clinical response in moderate-to-severe plaque-type psoriasis patients treated with infliximab in routine care settings of Greece.
    Petridis A; Panagakis P; Moustou E; Vergou T; Kallidis P; Mandekou-Lefaki I; Chaidemenos G; Sotiriadis D; Alexopoulou G; Haratsis Y; Antoniou C
    J Eur Acad Dermatol Venereol; 2018 May; 32(5):768-775. PubMed ID: 29356149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study.
    Crowley JJ; Langley RG; Gordon KB; Pinter A; Ferris LK; Rubant S; Photowala H; Xue Z; Wu T; Zhan T; Beeck S; Shah M; Warren RB
    Dermatol Ther (Heidelb); 2022 Feb; 12(2):561-575. PubMed ID: 35050485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical effectiveness and safety experience with alefacept in the treatment of patients with moderate-to-severe chronic plaque psoriasis in Taiwan: results of an open-label, single-arm, multicentre pilot study.
    Huang PH; Liao YH; Wei CC; Tseng YH; Ho JC; Tsai TF
    J Eur Acad Dermatol Venereol; 2008 Aug; 22(8):923-30. PubMed ID: 18312328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of health outcomes (PSoHO).
    Pinter A; Eyerich K; Costanzo A; Garrelts A; Schuster C; Mert C; Lampropoulou A; Fotiou K; Maul JT; Papp KA
    J Dermatolog Treat; 2024 Dec; 35(1):2350227. PubMed ID: 38797734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III Study.
    Cai L; Li L; Cheng H; Ding Y; Biao Z; Zhang S; Geng S; Liu Q; Fang H; Song Z; Lu Y; Li S; Guo Q; Tao J; He L; Gu J; Yang Q; Han X; Gao X; Deng D; Li S; Wang Q; Zhu J; Zhang J
    Adv Ther; 2022 Jan; 39(1):583-597. PubMed ID: 34816373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.
    Reich K; Papp KA; Blauvelt A; Tyring SK; Sinclair R; Thaçi D; Nograles K; Mehta A; Cichanowitz N; Li Q; Liu K; La Rosa C; Green S; Kimball AB
    Lancet; 2017 Jul; 390(10091):276-288. PubMed ID: 28596043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sex differences in the association between plasma polyunsaturated fatty acids levels and moderate-to-severe plaque psoriasis severity: a cross-sectional and longitudinal study.
    Wang X; Ma R; Shi R; Qin H; Chen W; Yu Z; Ding Y; Peng C; Shi Y
    J Transl Med; 2023 Nov; 21(1):834. PubMed ID: 37986112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial.
    Bissonnette R; Iversen L; Sofen H; Griffiths CE; Foley P; Romiti R; Bachinsky M; Rottinghaus ST; Tan H; Proulx J; Valdez H; Gupta P; Mallbris L; Wolk R
    Br J Dermatol; 2015; 172(5):1395-406. PubMed ID: 25418186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of bimekizumab in real-world psoriasis management: data from patients who are biologic-naive vs. biologic-experienced.
    Megna M; Ruggiero A; Torta G; Martora F; Bianco M; Potestio L
    Clin Exp Dermatol; 2024 Sep; 49(10):1186-1189. PubMed ID: 38655677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.